GLP-1 Receptor Agonists: New Frontiers and Challenges
Recently, a new class of drugs, based on GLP-1, are revolutionizing medicine and the treatment of patients with diabetes, obesity, and other disorders associated with obesity.
Insights
Insights by Benjamin Berkowitz
Dr. Benjamin (Benny) Berkowitz counsels innovative clients as they develop new products, protects their groundbreaking inventions, and helps them maximize the value of their intellectual property in furtherance of business goals and strategy.
Search Insights
16 search results for:
Clear AllBenjamin A. Berkowitz
Antibody Drug Conjugates Keep Growing: What You Need to Know
Since 2018, there has been an exponential growth of over US$60 billion of licensing deals involving Antibody Drug Conjugates (ADCs), with 2023 having at least 18 deals. ADCs worldwide are projected to reach US$20-30 billion per year in the near future.
USPTO Drops Proposed Rules on Terminal Disclaimers
Earlier in 2024, the U.S. Patent and Trademark Office proposed a sweeping set of rules imposing new requirements on terminal disclaimers filed to overcome obviousness-type double patenting rejections, and separately proposed to impose new terminal disclaimer fees that would increase exponentially over the course of examination.
Antibody Drug Conjugates Keep Growing: What You Need to Know
Since 2018, licensing deals totaling over $60 billion have been signed regarding Antibody Drug Conjugates (ADCs), with 2023 alone having at least 18 deals.
2024 Foley Tokyo IP Conference
Please join us on Wednesday, September 25, for the 2024 Foley Tokyo IP Conference — “Navigating the Business of Innovation: Insights on Patent Eligibility, AI, and Other Key IP Developments” — a half-day educational seminar that will guide you through the latest IP legal developments and their practical implications for business in the United States.
Cancer Drugs: Antibody Drug Conjugates (ADCs) Keep Growing
Over the past few years economic headwinds have resulted in fewer deals, with companies and private equity firms alike reassessing where to spend money.
FDA Approves Two Gene Therapies to Treat Sickle Cell Disease Including a CRISPR-Based Therapy
These new therapies harness the power of stem cells to help patients with sickle cell disease avoid vaso-oclusive events and crises.
Cannabis Mid-Year Update 2022
With record inflation and the uncertain outcomes of geopolitical issues roiling global markets, the cannabis industry has nevertheless continued unperturbed.
Reading the Leaves: What's in Store for Cannabis in 2021
On the heels of a year beset by turmoil and the myriad challenges caused by the global pandemic, the cannabis industry nevertheless entered 2021 poised for significant growth amid a landscape teeming with opportunity.